By designating only one reference listed drug since the standard to which all generic variations must be shown to generally be bioequivalent, FDA hopes in order to avoid probable significant variations between generic drugs as well as their brand name name counterpart. Affected person help plans (PAPs) are usually sponsored by pharmaceutical cor